RBCC Narrows List Of Regenerative Medicine Targets

Rainbow Coral Corp. (OTCBB: RBCC), a growth-oriented provider of cutting-edge biotechnology solutions, announced today that the company opened talks with its top target in the regenerative medicine industry this week regarding a possible partnership or acquisition.

RBCC’s potential target specializes in relieving chronic back pain from Degenerative Disc Disease using an innovative, patentable remedy derived from a patient’s own cells. The new procedure could have the potential to ease the suffering of billions of people while helping give RBCC a strong foothold in the explosive regenerative medicine market.

“We’ve targeted the most promising technology and development team we could find in this space because we believe in their product,” said RBCC CEO Patrick Brown. “We plan to get an agreement signed with them as soon as possible in order to begin making RBCC a part of the solution for chronic pain sufferers worldwide.”

Forecasters across the globe are calling regenerative health the future of medicine, and RBCC plans to be well-positioned to capitalize on the industry’s growth. In recent years, major discoveries in the usage of adult stem cells and biologics have led to promising advances in the treatment of illnesses from chronic back pain to leukemia and even AIDS. Some analysts expect the market for regenerative solutions to grow in value to more than $35 billion by 2019.

By acquiring or partnering with up-and-coming regenerative therapy companies, RBCC plans to compete in the biotechnology industry alongside NeoStem, Inc. (NASDAQ: NBS), Neuralstem, Inc. (NYSE: CUR), Smith & Nephew (NASDAQ: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).

For more information on RBCC’s other biotech initiatives, please visit  www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit  www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit  www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Copyright Business Wire 2010